Cytovia, Inc.

Cytovia, Inc. was founded to help pharmaceutical researchers discover novel new protease modulators from existing compound libraries. Cytovia’s services center around its proprietary technology for high-throughput screening in living cells, which is applicable to any protease for which the substrate recognition sequence is known. The company is focused initially on finding compounds that modulate caspases, the enzymes that trigger apoptosis or programmed cell death. Such compounds may prove therapeutic for cancer and degenerative and viral diseases. Using its technology, Cytovia already has discovered entirely new classes of small molecule drug leads. One class activates caspases in cancer cells independent of the tumor suppresser gene p53 and another class includes the most potent anti-apoptotic compounds known. The company is actively seeking pharmaceutical partners to develop these drug leads.

Activity:

Product / Technology type(s) covered:

- Enzymes
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: